Erratum to: A Phase 1 dose-escalation study of the safety and pharmacokinetics of once-daily oral foretinib, a multi-kinase inhibitor, in patients with solid tumors.

Invest New Drugs

Yale Cancer Center, New Haven, CT, USA.

Published: December 2015

Download full-text PDF	Source
http://dx.doi.org/10.1007/s10637-015-0287-6	DOI Listing

Publication Analysis

erratum phase

phase dose-escalation

dose-escalation study

study safety

safety pharmacokinetics

pharmacokinetics once-daily

once-daily oral

oral foretinib

foretinib multi-kinase

multi-kinase inhibitor

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!